John Kinsella
Concepts (678)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nitric Oxide | 88 | 2023 | 892 | 7.330 |
Why?
| | Hernias, Diaphragmatic, Congenital | 26 | 2024 | 221 | 5.810 |
Why?
| | Persistent Fetal Circulation Syndrome | 37 | 2023 | 138 | 4.750 |
Why?
| | Hypertension, Pulmonary | 46 | 2025 | 1957 | 3.290 |
Why?
| | Respiratory Insufficiency | 29 | 2023 | 326 | 3.210 |
Why?
| | Extracorporeal Membrane Oxygenation | 30 | 2024 | 390 | 2.840 |
Why?
| | Bronchopulmonary Dysplasia | 19 | 2025 | 420 | 2.520 |
Why?
| | Administration, Inhalation | 70 | 2023 | 571 | 2.330 |
Why?
| | Infant, Newborn | 108 | 2026 | 6464 | 2.060 |
Why?
| | Hemodynamics | 41 | 2025 | 1118 | 1.810 |
Why?
| | Infant, Premature | 31 | 2024 | 620 | 1.720 |
Why?
| | Bronchodilator Agents | 12 | 2020 | 187 | 1.700 |
Why?
| | High-Frequency Ventilation | 20 | 2006 | 45 | 1.670 |
Why?
| | Vasodilator Agents | 15 | 2022 | 330 | 1.550 |
Why?
| | Respiratory Distress Syndrome, Newborn | 13 | 2011 | 107 | 1.550 |
Why?
| | Oxygen Inhalation Therapy | 10 | 2015 | 181 | 1.440 |
Why?
| | Pulmonary Circulation | 31 | 2006 | 430 | 1.310 |
Why?
| | Hernia, Diaphragmatic | 9 | 2021 | 67 | 1.300 |
Why?
| | Infant, Premature, Diseases | 6 | 2019 | 113 | 1.190 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2022 | 394 | 1.140 |
Why?
| | Respiration, Artificial | 25 | 2019 | 714 | 0.970 |
Why?
| | Intensive Care Units | 7 | 2018 | 924 | 0.970 |
Why?
| | Hypoxia | 19 | 2021 | 1199 | 0.940 |
Why?
| | Oxygen | 21 | 2021 | 981 | 0.880 |
Why?
| | Vascular Resistance | 29 | 2021 | 370 | 0.870 |
Why?
| | Echocardiography | 13 | 2023 | 648 | 0.820 |
Why?
| | Humans | 172 | 2026 | 145750 | 0.790 |
Why?
| | Blood Gas Analysis | 7 | 2021 | 82 | 0.780 |
Why?
| | Gestational Age | 22 | 2024 | 989 | 0.750 |
Why?
| | Lung | 33 | 2023 | 4116 | 0.750 |
Why?
| | Transportation of Patients | 3 | 2020 | 65 | 0.730 |
Why?
| | Critical Care | 8 | 2017 | 702 | 0.710 |
Why?
| | Propofol | 5 | 2024 | 85 | 0.690 |
Why?
| | Bronchoconstriction | 1 | 2020 | 29 | 0.640 |
Why?
| | Ventricular Dysfunction | 1 | 2019 | 16 | 0.610 |
Why?
| | Sheep | 40 | 2007 | 876 | 0.610 |
Why?
| | Pulmonary Gas Exchange | 11 | 2009 | 116 | 0.600 |
Why?
| | Anaphylaxis | 1 | 2020 | 102 | 0.580 |
Why?
| | Pre-Eclampsia | 2 | 2024 | 206 | 0.580 |
Why?
| | Heart Atria | 1 | 2020 | 141 | 0.580 |
Why?
| | Fetus | 21 | 2018 | 804 | 0.570 |
Why?
| | Cardiovascular System | 1 | 2020 | 139 | 0.570 |
Why?
| | Vasodilation | 20 | 2005 | 521 | 0.570 |
Why?
| | Ductus Arteriosus, Patent | 4 | 2015 | 52 | 0.560 |
Why?
| | Infant | 36 | 2025 | 10089 | 0.560 |
Why?
| | Severity of Illness Index | 15 | 2025 | 2933 | 0.550 |
Why?
| | Hospital Mortality | 6 | 2018 | 1038 | 0.520 |
Why?
| | Heart Ventricles | 3 | 2020 | 756 | 0.510 |
Why?
| | Trachea | 2 | 2018 | 258 | 0.510 |
Why?
| | Critical Illness | 5 | 2017 | 900 | 0.500 |
Why?
| | Early Medical Intervention | 2 | 2014 | 63 | 0.500 |
Why?
| | Anesthetics, Intravenous | 4 | 2024 | 69 | 0.490 |
Why?
| | Pulmonary Surfactants | 6 | 2021 | 105 | 0.490 |
Why?
| | Liver Cirrhosis | 2 | 2015 | 287 | 0.480 |
Why?
| | Animals, Newborn | 18 | 2007 | 896 | 0.480 |
Why?
| | Monitoring, Physiologic | 3 | 2019 | 289 | 0.470 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 196 | 0.470 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 17 | 0.470 |
Why?
| | Hyaline Membrane Disease | 6 | 1998 | 20 | 0.460 |
Why?
| | Female | 83 | 2026 | 79025 | 0.460 |
Why?
| | Blood Coagulation | 1 | 2017 | 274 | 0.450 |
Why?
| | Pulmonary Artery | 20 | 2021 | 1129 | 0.450 |
Why?
| | Morphine | 1 | 2016 | 169 | 0.450 |
Why?
| | Umbilical Arteries | 1 | 2015 | 52 | 0.440 |
Why?
| | Radial Artery | 1 | 2015 | 75 | 0.440 |
Why?
| | Nerve Block | 1 | 2016 | 108 | 0.440 |
Why?
| | Ultrasonography, Interventional | 1 | 2016 | 166 | 0.430 |
Why?
| | Treatment Outcome | 27 | 2026 | 11793 | 0.430 |
Why?
| | Male | 65 | 2025 | 72992 | 0.410 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2016 | 183 | 0.400 |
Why?
| | Superoxide Dismutase | 2 | 2006 | 308 | 0.400 |
Why?
| | Vitamin A | 1 | 2013 | 62 | 0.400 |
Why?
| | Oxygen Consumption | 3 | 2015 | 719 | 0.390 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1582 | 0.390 |
Why?
| | Knowledge Bases | 1 | 2013 | 28 | 0.380 |
Why?
| | Vitamins | 1 | 2013 | 184 | 0.360 |
Why?
| | Phosphodiesterase Inhibitors | 5 | 2013 | 73 | 0.350 |
Why?
| | Alcohol-Related Disorders | 1 | 2013 | 121 | 0.340 |
Why?
| | Intestinal Obstruction | 1 | 2012 | 55 | 0.340 |
Why?
| | Retrospective Studies | 27 | 2024 | 17322 | 0.340 |
Why?
| | Muscle, Smooth, Vascular | 8 | 2005 | 450 | 0.330 |
Why?
| | Anesthesia, General | 2 | 2005 | 121 | 0.320 |
Why?
| | Lung Diseases | 6 | 2010 | 782 | 0.310 |
Why?
| | Paresis | 1 | 2010 | 30 | 0.310 |
Why?
| | Sulfones | 4 | 2013 | 127 | 0.300 |
Why?
| | Adrenal Insufficiency | 1 | 2010 | 31 | 0.300 |
Why?
| | Emergency Medicine | 1 | 2013 | 282 | 0.300 |
Why?
| | Dietary Supplements | 1 | 2013 | 584 | 0.300 |
Why?
| | Nitric Oxide Synthase | 15 | 2005 | 234 | 0.290 |
Why?
| | Decision Support Systems, Clinical | 1 | 2013 | 273 | 0.280 |
Why?
| | Survival Rate | 14 | 2022 | 2094 | 0.280 |
Why?
| | Dipyridamole | 6 | 1998 | 28 | 0.280 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2010 | 212 | 0.280 |
Why?
| | Herniorrhaphy | 2 | 2020 | 76 | 0.280 |
Why?
| | Pacemaker, Artificial | 1 | 2009 | 128 | 0.270 |
Why?
| | Nose | 2 | 2008 | 67 | 0.270 |
Why?
| | Meconium Aspiration Syndrome | 3 | 2003 | 11 | 0.270 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2011 | 293 | 0.270 |
Why?
| | Analgesics, Opioid | 1 | 2016 | 1154 | 0.260 |
Why?
| | Fluorocarbons | 2 | 1999 | 120 | 0.260 |
Why?
| | Pregnancy | 20 | 2026 | 7215 | 0.260 |
Why?
| | Heart Rate, Fetal | 3 | 2026 | 31 | 0.250 |
Why?
| | Cardiac Output | 8 | 2009 | 179 | 0.250 |
Why?
| | Heart Defects, Congenital | 7 | 2022 | 910 | 0.250 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2007 | 117 | 0.250 |
Why?
| | Foreign Bodies | 1 | 2008 | 110 | 0.250 |
Why?
| | Action Potentials | 1 | 2010 | 502 | 0.240 |
Why?
| | Child | 22 | 2025 | 22738 | 0.240 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3915 | 0.230 |
Why?
| | Anticoagulants | 2 | 2024 | 748 | 0.230 |
Why?
| | Pulmonary Alveoli | 4 | 2022 | 387 | 0.230 |
Why?
| | Thyroidectomy | 2 | 2024 | 94 | 0.230 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2013 | 920 | 0.230 |
Why?
| | Atrioventricular Block | 1 | 2026 | 44 | 0.230 |
Why?
| | Bradycardia | 1 | 2026 | 61 | 0.230 |
Why?
| | Animals | 60 | 2022 | 38100 | 0.230 |
Why?
| | Fetal Diseases | 3 | 2026 | 194 | 0.230 |
Why?
| | Piperazines | 3 | 2013 | 375 | 0.220 |
Why?
| | Respiration Disorders | 1 | 2005 | 78 | 0.210 |
Why?
| | Hirudins | 1 | 2024 | 53 | 0.210 |
Why?
| | Respiration | 3 | 2019 | 207 | 0.210 |
Why?
| | Muscle Stretching Exercises | 1 | 2024 | 19 | 0.210 |
Why?
| | Neck Pain | 1 | 2024 | 30 | 0.210 |
Why?
| | Tracheostomy | 2 | 2024 | 142 | 0.210 |
Why?
| | Antithrombins | 1 | 2024 | 71 | 0.210 |
Why?
| | Ventricular Function, Left | 6 | 2020 | 544 | 0.200 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 105 | 0.200 |
Why?
| | Heart | 3 | 2019 | 626 | 0.200 |
Why?
| | Preoperative Care | 3 | 2017 | 380 | 0.200 |
Why?
| | Ductus Arteriosus | 11 | 2005 | 72 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2020 | 2028 | 0.190 |
Why?
| | Heparin | 1 | 2024 | 247 | 0.190 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 69 | 0.190 |
Why?
| | Fatal Outcome | 4 | 2012 | 305 | 0.190 |
Why?
| | Double-Blind Method | 4 | 2016 | 2064 | 0.190 |
Why?
| | Nitrites | 1 | 2002 | 88 | 0.180 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2017 | 75 | 0.180 |
Why?
| | Antioxidants | 1 | 2006 | 550 | 0.180 |
Why?
| | Prospective Studies | 11 | 2023 | 8075 | 0.180 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 237 | 0.180 |
Why?
| | Respiratory Therapy | 3 | 2003 | 25 | 0.180 |
Why?
| | Incidence | 5 | 2015 | 2933 | 0.170 |
Why?
| | Risk Factors | 12 | 2024 | 10916 | 0.170 |
Why?
| | Prognosis | 7 | 2023 | 4329 | 0.170 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2001 | 42 | 0.170 |
Why?
| | Vasoconstriction | 3 | 2005 | 216 | 0.160 |
Why?
| | Precision Medicine | 2 | 2023 | 461 | 0.160 |
Why?
| | Peptide Fragments | 1 | 2024 | 696 | 0.160 |
Why?
| | Emergency Treatment | 1 | 2002 | 123 | 0.160 |
Why?
| | Plethysmography | 1 | 2001 | 104 | 0.160 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 544 | 0.160 |
Why?
| | Fundoplication | 1 | 2020 | 52 | 0.160 |
Why?
| | Cardiac Catheterization | 7 | 2025 | 559 | 0.160 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2020 | 33 | 0.160 |
Why?
| | Papio | 6 | 1995 | 70 | 0.160 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 63 | 0.150 |
Why?
| | Blood Pressure | 13 | 2014 | 1782 | 0.150 |
Why?
| | Carbon Monoxide | 1 | 2000 | 82 | 0.150 |
Why?
| | Fluid Therapy | 2 | 2011 | 155 | 0.150 |
Why?
| | Time Factors | 12 | 2017 | 7133 | 0.150 |
Why?
| | Logistic Models | 6 | 2024 | 2139 | 0.150 |
Why?
| | Middle Aged | 19 | 2019 | 36297 | 0.150 |
Why?
| | Pulmonary Veins | 2 | 1999 | 108 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2019 | 1751 | 0.140 |
Why?
| | Infusions, Intravenous | 4 | 2024 | 428 | 0.140 |
Why?
| | Postoperative Complications | 6 | 2017 | 2977 | 0.140 |
Why?
| | Thrombelastography | 1 | 2020 | 192 | 0.140 |
Why?
| | Patient Care Team | 2 | 2016 | 697 | 0.140 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1474 | 0.140 |
Why?
| | Combined Modality Therapy | 7 | 2017 | 1270 | 0.140 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2123 | 0.140 |
Why?
| | Treatment Failure | 5 | 2007 | 360 | 0.140 |
Why?
| | Aged | 15 | 2019 | 26212 | 0.140 |
Why?
| | Risk | 3 | 2021 | 923 | 0.140 |
Why?
| | United Kingdom | 3 | 2017 | 358 | 0.140 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 198 | 0.130 |
Why?
| | Child, Preschool | 15 | 2025 | 11866 | 0.130 |
Why?
| | Return to Work | 1 | 2017 | 21 | 0.130 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 90 | 0.130 |
Why?
| | Adult | 19 | 2026 | 40867 | 0.130 |
Why?
| | Single-Blind Method | 2 | 2013 | 318 | 0.130 |
Why?
| | Cerebral Hemorrhage | 2 | 2014 | 125 | 0.130 |
Why?
| | Heart Rate | 4 | 2009 | 856 | 0.130 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 199 | 0.130 |
Why?
| | Thiopental | 1 | 1997 | 13 | 0.130 |
Why?
| | Ondansetron | 1 | 1997 | 20 | 0.130 |
Why?
| | Pneumonectomy | 1 | 2019 | 167 | 0.130 |
Why?
| | Retinopathy of Prematurity | 1 | 2019 | 181 | 0.120 |
Why?
| | Troponin I | 1 | 2017 | 73 | 0.120 |
Why?
| | Registries | 6 | 2025 | 2410 | 0.120 |
Why?
| | Anesthesia, Spinal | 1 | 2016 | 13 | 0.120 |
Why?
| | Pulmonary Edema | 1 | 1997 | 105 | 0.120 |
Why?
| | Methemoglobin | 2 | 1993 | 24 | 0.120 |
Why?
| | Intubation, Intratracheal | 2 | 2018 | 327 | 0.120 |
Why?
| | Blood Circulation | 3 | 1998 | 44 | 0.120 |
Why?
| | Dyspnea | 1 | 2018 | 250 | 0.120 |
Why?
| | Smoke Inhalation Injury | 3 | 1991 | 29 | 0.120 |
Why?
| | Biological Products | 1 | 2000 | 257 | 0.120 |
Why?
| | Capillary Permeability | 1 | 1997 | 132 | 0.120 |
Why?
| | Anesthesia, Local | 1 | 2016 | 26 | 0.120 |
Why?
| | Glycocalyx | 1 | 2016 | 30 | 0.120 |
Why?
| | Follow-Up Studies | 10 | 2019 | 5428 | 0.120 |
Why?
| | Injections, Spinal | 1 | 2016 | 120 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2018 | 268 | 0.120 |
Why?
| | Antiemetics | 1 | 1997 | 51 | 0.120 |
Why?
| | Infant, Newborn, Diseases | 2 | 2014 | 115 | 0.120 |
Why?
| | Estradiol | 4 | 2001 | 515 | 0.120 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1547 | 0.120 |
Why?
| | Echocardiography, Doppler | 2 | 2001 | 115 | 0.120 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 14 | 0.120 |
Why?
| | Mentors | 1 | 2018 | 217 | 0.120 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 12 | 0.120 |
Why?
| | Survivors | 1 | 2019 | 523 | 0.120 |
Why?
| | Disease Management | 2 | 2017 | 653 | 0.120 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2019 | 248 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 740 | 0.120 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2016 | 37 | 0.110 |
Why?
| | Employment | 1 | 2017 | 184 | 0.110 |
Why?
| | Nitroarginine | 10 | 2005 | 57 | 0.110 |
Why?
| | Colorectal Neoplasms | 2 | 2016 | 868 | 0.110 |
Why?
| | Emergency Service, Hospital | 1 | 2008 | 2383 | 0.110 |
Why?
| | Chronic Disease | 8 | 2013 | 1810 | 0.110 |
Why?
| | Down Syndrome | 1 | 2022 | 525 | 0.110 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 271 | 0.110 |
Why?
| | Neutrophils | 3 | 1999 | 1125 | 0.110 |
Why?
| | Radiography | 2 | 2008 | 853 | 0.110 |
Why?
| | Length of Stay | 5 | 2017 | 1350 | 0.110 |
Why?
| | Academic Medical Centers | 1 | 2018 | 554 | 0.110 |
Why?
| | Hypnotics and Sedatives | 2 | 2024 | 222 | 0.110 |
Why?
| | Faculty, Medical | 1 | 2018 | 305 | 0.110 |
Why?
| | Sildenafil Citrate | 4 | 2021 | 60 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2015 | 283 | 0.110 |
Why?
| | Risk Assessment | 4 | 2017 | 3752 | 0.110 |
Why?
| | Postoperative Care | 1 | 2016 | 286 | 0.110 |
Why?
| | Cerebrovascular Circulation | 3 | 1995 | 290 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2011 | 552 | 0.100 |
Why?
| | Ventilator Weaning | 2 | 2005 | 40 | 0.100 |
Why?
| | Mothers | 1 | 2020 | 765 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 364 | 0.100 |
Why?
| | Ammonia | 2 | 1992 | 61 | 0.100 |
Why?
| | Vasopressins | 1 | 2014 | 61 | 0.100 |
Why?
| | Continuity of Patient Care | 1 | 2016 | 297 | 0.100 |
Why?
| | Biomarkers | 4 | 2016 | 4302 | 0.100 |
Why?
| | Pediatrics | 2 | 2019 | 1124 | 0.100 |
Why?
| | Thrombosis | 1 | 2017 | 400 | 0.100 |
Why?
| | Alcohol Withdrawal Delirium | 1 | 2013 | 9 | 0.100 |
Why?
| | Vasoconstrictor Agents | 1 | 2014 | 150 | 0.100 |
Why?
| | Survival Analysis | 3 | 2009 | 1378 | 0.100 |
Why?
| | Elective Surgical Procedures | 2 | 2011 | 203 | 0.100 |
Why?
| | Hypotension | 1 | 2014 | 127 | 0.100 |
Why?
| | Clinical Trials as Topic | 3 | 2008 | 1062 | 0.090 |
Why?
| | Epoprostenol | 3 | 2021 | 132 | 0.090 |
Why?
| | Cell Nucleus | 1 | 1996 | 588 | 0.090 |
Why?
| | Cyclic GMP | 4 | 2001 | 90 | 0.090 |
Why?
| | Coronary Circulation | 2 | 1995 | 134 | 0.090 |
Why?
| | Pilot Projects | 5 | 2024 | 1897 | 0.090 |
Why?
| | Diaphragm | 2 | 2023 | 48 | 0.090 |
Why?
| | Critical Care Nursing | 1 | 2013 | 48 | 0.090 |
Why?
| | Renal Dialysis | 1 | 2016 | 466 | 0.090 |
Why?
| | Hemorrhage | 1 | 2017 | 822 | 0.090 |
Why?
| | Vascular Diseases | 1 | 2015 | 252 | 0.090 |
Why?
| | Early Diagnosis | 1 | 2013 | 251 | 0.090 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2011 | 9 | 0.090 |
Why?
| | Recombinant Proteins | 2 | 2024 | 1368 | 0.090 |
Why?
| | Delivery Rooms | 1 | 2011 | 10 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2017 | 8346 | 0.080 |
Why?
| | Diseases in Twins | 1 | 2012 | 116 | 0.080 |
Why?
| | Troponin | 1 | 2011 | 50 | 0.080 |
Why?
| | Kidney Tubules | 1 | 1992 | 118 | 0.080 |
Why?
| | Cohort Studies | 5 | 2024 | 6032 | 0.080 |
Why?
| | Ventilators, Mechanical | 2 | 2016 | 71 | 0.080 |
Why?
| | Acetylcholine | 5 | 2001 | 209 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2018 | 3634 | 0.080 |
Why?
| | Respiratory Mechanics | 3 | 1999 | 74 | 0.080 |
Why?
| | Cardiac Output, Low | 1 | 1991 | 53 | 0.080 |
Why?
| | Algorithms | 3 | 2013 | 1850 | 0.080 |
Why?
| | Patient Admission | 1 | 2013 | 220 | 0.080 |
Why?
| | Alfentanil | 1 | 2010 | 7 | 0.080 |
Why?
| | Monitoring, Intraoperative | 2 | 2008 | 66 | 0.080 |
Why?
| | Oocyte Retrieval | 1 | 2010 | 17 | 0.080 |
Why?
| | Delivery, Obstetric | 1 | 1991 | 160 | 0.080 |
Why?
| | Nitric Oxide Synthase Type III | 7 | 2007 | 203 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 190 | 0.080 |
Why?
| | DNA-Binding Proteins | 2 | 2007 | 1482 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 177 | 0.080 |
Why?
| | Thermodilution | 2 | 2005 | 16 | 0.080 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 237 | 0.080 |
Why?
| | Disease Models, Animal | 7 | 2007 | 4569 | 0.080 |
Why?
| | Endothelium, Vascular | 5 | 2016 | 956 | 0.080 |
Why?
| | Platelet-Derived Growth Factor | 2 | 2003 | 85 | 0.080 |
Why?
| | APACHE | 2 | 2017 | 68 | 0.080 |
Why?
| | Communication | 1 | 2016 | 976 | 0.080 |
Why?
| | Physicians | 1 | 2018 | 956 | 0.070 |
Why?
| | Analysis of Variance | 6 | 2014 | 1300 | 0.070 |
Why?
| | Airway Obstruction | 1 | 1991 | 153 | 0.070 |
Why?
| | Abdomen | 1 | 2010 | 142 | 0.070 |
Why?
| | Endothelin Receptor Antagonists | 3 | 1998 | 61 | 0.070 |
Why?
| | Endothelins | 3 | 2000 | 61 | 0.070 |
Why?
| | Vitamin D | 1 | 2012 | 404 | 0.070 |
Why?
| | Positive-Pressure Respiration | 2 | 2000 | 115 | 0.070 |
Why?
| | Prostaglandins | 2 | 2001 | 94 | 0.070 |
Why?
| | Thoracic Surgical Procedures | 1 | 2010 | 94 | 0.070 |
Why?
| | Anesthetics, Combined | 1 | 2008 | 7 | 0.070 |
Why?
| | Regional Blood Flow | 4 | 1998 | 514 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 484 | 0.070 |
Why?
| | Patient Readmission | 1 | 2013 | 772 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2460 | 0.070 |
Why?
| | Chest Wall Oscillation | 1 | 2007 | 5 | 0.070 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 189 | 0.070 |
Why?
| | Scotland | 2 | 2018 | 38 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 298 | 0.070 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2011 | 339 | 0.070 |
Why?
| | Transcription Factors | 1 | 1996 | 1736 | 0.060 |
Why?
| | Receptors, Endothelin | 3 | 2000 | 48 | 0.060 |
Why?
| | Postoperative Period | 3 | 2016 | 351 | 0.060 |
Why?
| | Acute Disease | 2 | 2005 | 1036 | 0.060 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 1998 | 17 | 0.060 |
Why?
| | Sex Distribution | 1 | 2008 | 388 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2004 | 109 | 0.060 |
Why?
| | Microspheres | 3 | 1991 | 142 | 0.060 |
Why?
| | Leukomalacia, Periventricular | 1 | 2006 | 9 | 0.060 |
Why?
| | Lung Neoplasms | 2 | 2019 | 2667 | 0.060 |
Why?
| | Purines | 3 | 2013 | 187 | 0.060 |
Why?
| | Piperidines | 1 | 2008 | 222 | 0.060 |
Why?
| | Neoplasms | 2 | 2019 | 2913 | 0.060 |
Why?
| | Endothelin-1 | 5 | 2000 | 181 | 0.060 |
Why?
| | Swine | 2 | 2003 | 826 | 0.060 |
Why?
| | Umbilical Cord | 1 | 2026 | 93 | 0.060 |
Why?
| | Enzyme Inhibitors | 7 | 2005 | 821 | 0.060 |
Why?
| | Atrial Natriuretic Factor | 2 | 1996 | 55 | 0.060 |
Why?
| | Intracranial Hemorrhages | 1 | 2006 | 106 | 0.060 |
Why?
| | Lung Compliance | 1 | 2005 | 42 | 0.060 |
Why?
| | Methyl Ethers | 1 | 2005 | 19 | 0.060 |
Why?
| | Epinephrine | 1 | 2026 | 158 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 1998 | 610 | 0.060 |
Why?
| | Airway Resistance | 1 | 2005 | 38 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 35 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2010 | 1150 | 0.050 |
Why?
| | Signal Transduction | 3 | 2005 | 5223 | 0.050 |
Why?
| | Prenatal Care | 1 | 2007 | 309 | 0.050 |
Why?
| | Electric Impedance | 1 | 2005 | 108 | 0.050 |
Why?
| | Anesthetics, Inhalation | 1 | 2005 | 52 | 0.050 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 298 | 0.050 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2022 | 67 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2006 | 2967 | 0.050 |
Why?
| | Amides | 1 | 2005 | 101 | 0.050 |
Why?
| | Drug Administration Schedule | 4 | 2011 | 782 | 0.050 |
Why?
| | Carbon Dioxide | 4 | 1999 | 227 | 0.050 |
Why?
| | Electroencephalography | 1 | 2008 | 563 | 0.050 |
Why?
| | Aging | 2 | 1992 | 1973 | 0.050 |
Why?
| | Rats | 7 | 2005 | 5585 | 0.050 |
Why?
| | Cesarean Section | 1 | 2026 | 230 | 0.050 |
Why?
| | Carcinoma | 2 | 2016 | 227 | 0.050 |
Why?
| | Home Nursing | 1 | 2003 | 24 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1372 | 0.050 |
Why?
| | Bronchoalveolar Lavage | 1 | 2003 | 89 | 0.050 |
Why?
| | Cost-Benefit Analysis | 3 | 2011 | 644 | 0.050 |
Why?
| | Birth Weight | 1 | 2006 | 517 | 0.050 |
Why?
| | Esophagus | 1 | 2005 | 262 | 0.050 |
Why?
| | Coronary Artery Bypass | 1 | 2005 | 268 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 62 | 0.050 |
Why?
| | Forced Expiratory Volume | 2 | 2016 | 450 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2024 | 311 | 0.050 |
Why?
| | Embryonic and Fetal Development | 3 | 2000 | 93 | 0.050 |
Why?
| | Lymphokines | 1 | 2002 | 128 | 0.050 |
Why?
| | Intermittent Positive-Pressure Ventilation | 2 | 1993 | 12 | 0.050 |
Why?
| | Surgical Flaps | 1 | 2023 | 142 | 0.050 |
Why?
| | Age Factors | 3 | 2016 | 3346 | 0.050 |
Why?
| | Mouth Mucosa | 1 | 2022 | 85 | 0.050 |
Why?
| | Stomach | 1 | 2002 | 111 | 0.040 |
Why?
| | Sequence Deletion | 1 | 2022 | 191 | 0.040 |
Why?
| | Mosaicism | 1 | 2022 | 73 | 0.040 |
Why?
| | Analgesics | 1 | 2024 | 231 | 0.040 |
Why?
| | Evaluation Studies as Topic | 2 | 1992 | 164 | 0.040 |
Why?
| | Phenotype | 2 | 2023 | 3170 | 0.040 |
Why?
| | Estrogen Antagonists | 1 | 2001 | 37 | 0.040 |
Why?
| | Thyroid Neoplasms | 2 | 2016 | 370 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 209 | 0.040 |
Why?
| | Uterus | 1 | 2002 | 228 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5921 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2002 | 376 | 0.040 |
Why?
| | Muscle, Smooth | 2 | 2000 | 153 | 0.040 |
Why?
| | Milrinone | 1 | 2021 | 26 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2001 | 68 | 0.040 |
Why?
| | Ligation | 5 | 2002 | 91 | 0.040 |
Why?
| | Calibration | 1 | 2001 | 152 | 0.040 |
Why?
| | Injections, Intra-Arterial | 1 | 2000 | 26 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2000 | 16 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 6084 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 875 | 0.040 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 5 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 134 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2883 | 0.040 |
Why?
| | Blotting, Northern | 4 | 2000 | 203 | 0.040 |
Why?
| | Potassium Channel Blockers | 1 | 1999 | 47 | 0.040 |
Why?
| | Angiography | 1 | 1999 | 208 | 0.040 |
Why?
| | Patient Transfer | 1 | 2002 | 211 | 0.040 |
Why?
| | Adolescent | 8 | 2005 | 22569 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 1999 | 249 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2001 | 404 | 0.030 |
Why?
| | Blood Vessels | 1 | 2000 | 167 | 0.030 |
Why?
| | Digestive System Physiological Phenomena | 1 | 1998 | 5 | 0.030 |
Why?
| | Leukocyte Count | 2 | 1997 | 318 | 0.030 |
Why?
| | Drug Synergism | 2 | 1998 | 354 | 0.030 |
Why?
| | Acidosis | 2 | 1992 | 105 | 0.030 |
Why?
| | Esophageal Neoplasms | 1 | 2002 | 348 | 0.030 |
Why?
| | Asphyxia Neonatorum | 1 | 1998 | 21 | 0.030 |
Why?
| | Body Weight | 2 | 2005 | 972 | 0.030 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 1998 | 55 | 0.030 |
Why?
| | Immunohistochemistry | 4 | 2005 | 1723 | 0.030 |
Why?
| | Receptor, Endothelin A | 4 | 2000 | 60 | 0.030 |
Why?
| | Occipital Bone | 1 | 1997 | 18 | 0.030 |
Why?
| | Frontal Bone | 1 | 1997 | 19 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2002 | 641 | 0.030 |
Why?
| | Cephalometry | 1 | 1997 | 30 | 0.030 |
Why?
| | Potassium Channels | 1 | 1998 | 148 | 0.030 |
Why?
| | Growth | 1 | 1997 | 49 | 0.030 |
Why?
| | Disease Progression | 2 | 2017 | 2865 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 1998 | 2883 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 145 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 134 | 0.030 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2016 | 23 | 0.030 |
Why?
| | Syndecan-1 | 1 | 2016 | 43 | 0.030 |
Why?
| | Expectorants | 1 | 2016 | 23 | 0.030 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2016 | 20 | 0.030 |
Why?
| | Nausea | 1 | 1997 | 112 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 196 | 0.030 |
Why?
| | Endothelin-3 | 1 | 1996 | 3 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 2019 | 297 | 0.030 |
Why?
| | Arginine | 2 | 1994 | 264 | 0.030 |
Why?
| | Rats, Inbred Strains | 3 | 1992 | 321 | 0.030 |
Why?
| | Interferon-Stimulated Gene Factor 3 | 1 | 1996 | 1 | 0.030 |
Why?
| | Ireland | 1 | 2016 | 32 | 0.030 |
Why?
| | Vascular Patency | 1 | 2016 | 121 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 203 | 0.030 |
Why?
| | Interrupted Time Series Analysis | 1 | 2016 | 75 | 0.030 |
Why?
| | Arteriovenous Fistula | 1 | 2016 | 38 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 1996 | 39 | 0.030 |
Why?
| | Vomiting | 1 | 1997 | 131 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 280 | 0.030 |
Why?
| | Kidney | 3 | 1991 | 1498 | 0.030 |
Why?
| | Patient Selection | 1 | 2000 | 739 | 0.030 |
Why?
| | Substance Withdrawal Syndrome | 1 | 1998 | 185 | 0.030 |
Why?
| | Gastrostomy | 1 | 1997 | 130 | 0.030 |
Why?
| | Luciferases | 1 | 1996 | 154 | 0.030 |
Why?
| | Blotting, Western | 3 | 2005 | 1184 | 0.030 |
Why?
| | Stroke Volume | 1 | 2019 | 655 | 0.030 |
Why?
| | Steroids | 1 | 2016 | 160 | 0.030 |
Why?
| | Lung Injury | 2 | 2011 | 249 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1512 | 0.030 |
Why?
| | Tyrosine | 1 | 1996 | 217 | 0.030 |
Why?
| | Genetic Counseling | 1 | 2015 | 80 | 0.030 |
Why?
| | Genes, Reporter | 1 | 1996 | 277 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 1997 | 217 | 0.030 |
Why?
| | Indiana | 1 | 2015 | 38 | 0.030 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2015 | 61 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 3 | 2001 | 162 | 0.030 |
Why?
| | Peptides, Cyclic | 4 | 1998 | 273 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2001 | 655 | 0.030 |
Why?
| | Biological Transport | 3 | 1991 | 424 | 0.030 |
Why?
| | Base Sequence | 2 | 1996 | 2171 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 1997 | 324 | 0.030 |
Why?
| | Endothelium | 1 | 1995 | 119 | 0.030 |
Why?
| | Aorta | 4 | 1998 | 440 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 222 | 0.030 |
Why?
| | Self Efficacy | 1 | 2017 | 411 | 0.030 |
Why?
| | Cardiovascular Agents | 1 | 2015 | 166 | 0.030 |
Why?
| | Organ Dysfunction Scores | 1 | 2014 | 55 | 0.030 |
Why?
| | Costs and Cost Analysis | 2 | 2009 | 221 | 0.030 |
Why?
| | Vasomotor System | 3 | 2002 | 47 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 688 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2015 | 156 | 0.030 |
Why?
| | Blood Flow Velocity | 2 | 1992 | 421 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1996 | 372 | 0.030 |
Why?
| | Life Support Care | 1 | 2014 | 42 | 0.020 |
Why?
| | Drug Evaluation | 1 | 1993 | 79 | 0.020 |
Why?
| | Area Under Curve | 1 | 2014 | 332 | 0.020 |
Why?
| | Stress, Mechanical | 3 | 2001 | 494 | 0.020 |
Why?
| | Schools, Medical | 1 | 2015 | 159 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1992 | 1049 | 0.020 |
Why?
| | Asthma | 1 | 2005 | 1797 | 0.020 |
Why?
| | Reference Values | 3 | 2002 | 798 | 0.020 |
Why?
| | Acute Lung Injury | 1 | 2016 | 307 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 666 | 0.020 |
Why?
| | Hypertension | 1 | 2002 | 1276 | 0.020 |
Why?
| | DNA | 2 | 1998 | 1437 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 337 | 0.020 |
Why?
| | Lactic Acid | 1 | 2014 | 295 | 0.020 |
Why?
| | Young Adult | 1 | 2009 | 14250 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 1997 | 521 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2874 | 0.020 |
Why?
| | Ammonium Chloride | 1 | 1992 | 4 | 0.020 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2012 | 74 | 0.020 |
Why?
| | Brain Chemistry | 1 | 1992 | 120 | 0.020 |
Why?
| | Child Development | 1 | 1997 | 483 | 0.020 |
Why?
| | ROC Curve | 1 | 2014 | 618 | 0.020 |
Why?
| | Nephrons | 1 | 1992 | 23 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2015 | 332 | 0.020 |
Why?
| | United States | 3 | 2012 | 16122 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 981 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1899 | 0.020 |
Why?
| | Streptococcus agalactiae | 1 | 1993 | 110 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 2011 | 42 | 0.020 |
Why?
| | Brain | 2 | 1997 | 2969 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 208 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 76 | 0.020 |
Why?
| | Quality of Life | 2 | 2017 | 3210 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 1995 | 381 | 0.020 |
Why?
| | Odds Ratio | 1 | 2014 | 1083 | 0.020 |
Why?
| | Phosphorylation | 1 | 1996 | 1708 | 0.020 |
Why?
| | Carboxyhemoglobin | 1 | 1991 | 7 | 0.020 |
Why?
| | Radioisotopes | 1 | 1991 | 37 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1247 | 0.020 |
Why?
| | Body Constitution | 1 | 1991 | 51 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 1993 | 171 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2003 | 149 | 0.020 |
Why?
| | Patient Discharge | 1 | 2017 | 995 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 788 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 1992 | 196 | 0.020 |
Why?
| | Sex Factors | 1 | 2016 | 2110 | 0.020 |
Why?
| | Echovirus Infections | 1 | 1990 | 1 | 0.020 |
Why?
| | RNA, Messenger | 3 | 2007 | 2805 | 0.020 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1993 | 288 | 0.020 |
Why?
| | Enterovirus B, Human | 1 | 1990 | 25 | 0.020 |
Why?
| | Preoperative Period | 1 | 2010 | 149 | 0.020 |
Why?
| | Meningoencephalitis | 1 | 1990 | 24 | 0.020 |
Why?
| | Medical Audit | 1 | 2010 | 77 | 0.020 |
Why?
| | Guanidines | 2 | 2001 | 39 | 0.020 |
Why?
| | Isoenzymes | 2 | 2001 | 295 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2009 | 132 | 0.020 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2001 | 82 | 0.020 |
Why?
| | Burns | 2 | 1991 | 374 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 125 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2012 | 401 | 0.020 |
Why?
| | Tetraethylammonium | 2 | 1999 | 16 | 0.020 |
Why?
| | Pressure | 2 | 2002 | 226 | 0.020 |
Why?
| | 4-Aminopyridine | 2 | 1999 | 30 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 1991 | 373 | 0.020 |
Why?
| | Heart Diseases | 1 | 1992 | 341 | 0.020 |
Why?
| | Constriction | 2 | 1999 | 45 | 0.020 |
Why?
| | Immunologic Techniques | 2 | 1999 | 38 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1996 | 4151 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 2007 | 9 | 0.020 |
Why?
| | Organ Size | 2 | 2005 | 461 | 0.020 |
Why?
| | Receptor, Endothelin B | 2 | 2000 | 43 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1001 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2007 | 27 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1990 | 638 | 0.020 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 46 | 0.020 |
Why?
| | Protein Precursors | 2 | 2000 | 136 | 0.020 |
Why?
| | Developmental Disabilities | 1 | 2009 | 281 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 875 | 0.010 |
Why?
| | RNA, Viral | 1 | 1990 | 692 | 0.010 |
Why?
| | Proteins | 1 | 1992 | 1023 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1662 | 0.010 |
Why?
| | Thoracic Diseases | 1 | 2005 | 11 | 0.010 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1987 | 199 | 0.010 |
Why?
| | Respiratory Muscles | 1 | 2005 | 37 | 0.010 |
Why?
| | Phosphates | 1 | 1986 | 177 | 0.010 |
Why?
| | Oscillometry | 1 | 2005 | 35 | 0.010 |
Why?
| | Manometry | 1 | 2005 | 98 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 86 | 0.010 |
Why?
| | Hypertrophy | 1 | 2005 | 128 | 0.010 |
Why?
| | Muscular Diseases | 1 | 2005 | 109 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4556 | 0.010 |
Why?
| | Pulse Therapy, Drug | 1 | 2003 | 7 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1139 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 396 | 0.010 |
Why?
| | Administration, Intranasal | 1 | 2003 | 94 | 0.010 |
Why?
| | Time | 1 | 2003 | 84 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 979 | 0.010 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 2002 | 4 | 0.010 |
Why?
| | Pharyngectomy | 1 | 2002 | 4 | 0.010 |
Why?
| | Speech, Alaryngeal | 1 | 2002 | 3 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 523 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 31 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 78 | 0.010 |
Why?
| | Pyrroles | 1 | 2004 | 220 | 0.010 |
Why?
| | Laryngectomy | 1 | 2002 | 17 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1987 | 729 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 53 | 0.010 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2002 | 85 | 0.010 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2002 | 58 | 0.010 |
Why?
| | Nifedipine | 1 | 2002 | 27 | 0.010 |
Why?
| | Meclofenamic Acid | 1 | 2001 | 9 | 0.010 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 18 | 0.010 |
Why?
| | Glucocorticoids | 1 | 1986 | 532 | 0.010 |
Why?
| | Clinical Competence | 1 | 2010 | 1247 | 0.010 |
Why?
| | Cyclooxygenase 1 | 1 | 2001 | 27 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 153 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 428 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 61 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 668 | 0.010 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2001 | 65 | 0.010 |
Why?
| | Lymph Node Excision | 1 | 2002 | 173 | 0.010 |
Why?
| | Esophagectomy | 1 | 2002 | 135 | 0.010 |
Why?
| | Amidines | 1 | 2001 | 13 | 0.010 |
Why?
| | Benzylamines | 1 | 2001 | 44 | 0.010 |
Why?
| | Pulmonary Ventilation | 1 | 2001 | 82 | 0.010 |
Why?
| | Calcium Channels | 1 | 2002 | 157 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 166 | 0.010 |
Why?
| | Cyclooxygenase 2 | 1 | 2001 | 167 | 0.010 |
Why?
| | Organ Specificity | 1 | 2001 | 309 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 668 | 0.010 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 162 | 0.010 |
Why?
| | Drug Interactions | 1 | 2001 | 405 | 0.010 |
Why?
| | Indoles | 1 | 2004 | 507 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1191 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 69 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 1999 | 46 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2525 | 0.010 |
Why?
| | Charybdotoxin | 1 | 1999 | 4 | 0.010 |
Why?
| | Atrial Function, Right | 1 | 1998 | 14 | 0.010 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 664 | 0.010 |
Why?
| | Delayed Rectifier Potassium Channels | 1 | 1998 | 9 | 0.010 |
Why?
| | Shab Potassium Channels | 1 | 1998 | 20 | 0.010 |
Why?
| | Digestive System | 1 | 1998 | 29 | 0.010 |
Why?
| | Electric Conductivity | 1 | 1998 | 85 | 0.010 |
Why?
| | Xenopus | 1 | 1998 | 87 | 0.010 |
Why?
| | Isothiuronium | 1 | 1998 | 3 | 0.010 |
Why?
| | Thiazines | 1 | 1998 | 13 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1478 | 0.010 |
Why?
| | Masks | 1 | 1998 | 70 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1998 | 273 | 0.010 |
Why?
| | Catheterization | 1 | 1998 | 184 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 910 | 0.010 |
Why?
| | Long-Term Care | 1 | 1998 | 118 | 0.010 |
Why?
| | Medical Records | 1 | 1998 | 192 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 538 | 0.010 |
Why?
| | Oocytes | 1 | 1998 | 185 | 0.010 |
Why?
| | Methylene Blue | 1 | 1996 | 24 | 0.010 |
Why?
| | Indomethacin | 1 | 1996 | 76 | 0.010 |
Why?
| | Dogs | 1 | 1998 | 478 | 0.010 |
Why?
| | Microvilli | 2 | 1987 | 75 | 0.010 |
Why?
| | Adenosine | 1 | 1998 | 255 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1996 | 153 | 0.010 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 1995 | 8 | 0.010 |
Why?
| | Purinones | 1 | 1995 | 4 | 0.010 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 1995 | 10 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 174 | 0.010 |
Why?
| | Receptors, Purinergic P1 | 1 | 1995 | 30 | 0.010 |
Why?
| | Theophylline | 1 | 1995 | 41 | 0.010 |
Why?
| | Adenocarcinoma, Follicular | 1 | 1995 | 43 | 0.010 |
Why?
| | Sodium | 2 | 1987 | 198 | 0.010 |
Why?
| | Arterioles | 1 | 1995 | 52 | 0.010 |
Why?
| | Carcinoma, Papillary | 1 | 1995 | 82 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 84 | 0.010 |
Why?
| | Phenylephrine | 1 | 1995 | 74 | 0.010 |
Why?
| | Home Care Services | 1 | 1998 | 284 | 0.010 |
Why?
| | Adrenal Glands | 1 | 1995 | 76 | 0.010 |
Why?
| | Renal Circulation | 1 | 1995 | 75 | 0.010 |
Why?
| | Viper Venoms | 1 | 1994 | 6 | 0.010 |
Why?
| | Muscle Tonus | 1 | 1994 | 24 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1998 | 2131 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1995 | 508 | 0.010 |
Why?
| | Forecasting | 1 | 1995 | 390 | 0.010 |
Why?
| | Cause of Death | 1 | 1995 | 471 | 0.010 |
Why?
| | Perfusion | 1 | 1994 | 251 | 0.010 |
Why?
| | Intestines | 1 | 1995 | 354 | 0.010 |
Why?
| | Chemotaxis | 1 | 1991 | 122 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 1995 | 562 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1991 | 181 | 0.000 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1990 | 25 | 0.000 |
Why?
| | Agammaglobulinemia | 1 | 1990 | 36 | 0.000 |
Why?
| | Nucleic Acid Hybridization | 1 | 1990 | 187 | 0.000 |
Why?
| | Gene Amplification | 1 | 1990 | 118 | 0.000 |
Why?
| | Cell Count | 1 | 1990 | 319 | 0.000 |
Why?
| | Myocardial Contraction | 1 | 1990 | 293 | 0.000 |
Why?
| | Adenocarcinoma | 1 | 1995 | 926 | 0.000 |
Why?
| | Eosinophils | 1 | 1990 | 316 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1987 | 27 | 0.000 |
Why?
| | Sodium-Hydrogen Exchangers | 1 | 1987 | 23 | 0.000 |
Why?
| | Polymerase Chain Reaction | 1 | 1990 | 1043 | 0.000 |
Why?
| | Monocytes | 1 | 1990 | 539 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1987 | 532 | 0.000 |
Why?
| | Skin | 1 | 1990 | 754 | 0.000 |
Why?
| | Glomerular Filtration Rate | 1 | 1987 | 765 | 0.000 |
Why?
| | Macrophages | 1 | 1990 | 1507 | 0.000 |
Why?
|
|
Kinsella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|